Acambis Suspends Smallpox Vaccine Trials Due To Cardiac Safety Concerns

Three suspected cases of myopericarditis were seen in one Phase III trial of ACAM2000 versus DryVax. Acambis expects to share follow-up data with FDA and CDC in eight to 12 weeks.